Latest news

• Avanir’s week goes from bad to worse with Alzheimer’s stumble

  AVP-786 is a second-generation version of Nuedexta, modified by the addition of deuterium into the dextromethorphan molecule. ... At the time, it said AVP-786 was one of the main attractions of the business.

• Otsuka’s Alzheimer’s agitation drug hits the mark

  The first trial readout from the companies’ phase 3 programme for AVP-786 (deudextromethorphan/quinidine) showed that the drug was able to achieve a significant reduction in agitation symptoms at one ... All three drug classes have side effect issues,

• Otsuka expands CNS presence with Avanir purchase

  Avanir also has a promising pipeline, including the compound AVP-786, which is being prepared for phase III trials investigating its use in agitation in people with Alzheimer's disease.